CONTACT
ABOUT ABBOTT
cardiovascular
MY ACCOUNT

Xience™ Family of Drug Eluting Stents

The world's leading drug eluting stents (DES)

Xience™ drug-eluting stents
Xience™ drug-eluting stents
Xience™ drug-eluting stents

  


Uncover insights into stent thromboresistance in this summary of the CVPath Institute, Inc. experiment comparing 4 stent surfaces (1:30-min)

  


Discover more: Watch the full video of the CVPath Institute, Inc. experiment comparing 4 stent surfaces.

  


Discover the unique design of XIENCE™ in this short video.

   

Unique Design Icon Unique Design Icon

Unique Design

Discover More
Acute Performance icon Acute Performance icon

Acute Performance

Discover More
Lasting Outcomes icon Lasting Outcomes icon

Lasting Outcomes

Discover More

Unique Design

XIENCE™ Stent is uniquely designed for exceptional performance1,2

Designed to deliver uncompromising clinical success based on a unique combination of stent design, fluoropolymer and drug.

XIENCE Serra image XIENCE Serra image

Innovative Stent Design

Anti-Thrombotic Fluoropolymer1

everolimus ball strucutre everolimus ball strucutre

Market-Leading Everolimus2

Acute Performance

XIENCE™ Stent shows excellent early outcomes in patients with acute myocardial infarction (AMI)3

XIENCE™ Stent showed significant improvement 2 weeks after PCI3:

  • Better Strut Coverage (p<0.01)
  • Less Thrombus (p=0.03)
  • Larger Lumen Area (p=0.048)
acute myocardial infarction post PCI acute myocardial infarction post PCI

Post-PCI

acute myocardial infarction 2 week post PCI acute myocardial infarction 2 week post PCI

2 Weeks Post-PCI

Demonstrated safety in patients with ST-Elevation Myocardial Infarction (STEMI)4

4x Lower 4x Lower

Definite stent thrombosis with XIENCE™ stent compared to BMS in STEMI patients at 30 days (0.4% vs 1.6%, p=0.02)

XIENCE™ Stent shows excellent early outcomes in complex patients5-7

Bifurcations lesions5

Excellent early outcomes in bifurcations
0.0% Def. ST at 30 days

Calcified lesions6

Excellent early outcomes in
calcified lesions
0.0% Def. ST at 30 days

Long lesions7

Excellent early outcomes in long lesions
0.3% Def. ST at 30 days

XIENCE™ Stent has significantly lower rates of acute and early stent thrombosis than Synergy‡ and Resolute‡8,9

Definite stent thrombosis at 24 hours8

Definite Stent Thrombosis at 24 hours graph Definite Stent Thrombosis at 24 hours graph

Definite stent thrombosis at 30 days9

Definite Stent Thrombosis at 30 days graph Definite Stent Thrombosis at 30 days graph

Lasting Outcomes

XIENCE™ Stent has the largest body of DAPT patient evidence10

XIENCE Revital data table - 20,000 patients alanysed XIENCE Revital data table - 20,000 patients alanysed

CONSISTENTLY LOW STENT THROMBOSIS (ST) RATES WITH 1-MONTH DAPT12

≤0.1% Definite ST rate at 12 months for 3 short DAPT analyses14

XIENCE™ Stent is supported by unmatched real-world patient evidence, consistently delivering outstanding short-and-long-term outcomes.15,16

120 clinical trials 10 years of clinical data 120 clinical trials 10 years of clinical data

Abbott’s Coronary Intervention Portfolio

 

 

™ Indicates a trademark of the Abbott Group of Companies.
‡ Indicates a third-party trademark, which is property of its respective owner.

References:

1. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:Suppl B – TCT-291. 
2. Data on file at Abbott. 
3. Morino Y, et al. Cardiovasc Interv and Ther. 2019;34:14-24. 
4. Sabate M, et al. Lancet. 2012;380:1482-1490. 
5. Dzivak V, Catheter Cardiovasc Interv. 2013;82(3):E163-E172. 
6. Onuma Y, et al. Catheter Cardiovasc Interv. 2010;76:634–642. 
7. Hong S, et al. Am Coll Cardiol Intv 2016;9:1438–1446. 
8. Zanchin, C. et al. J Am Coll Cardiol Intv. 2019;12(17):1665-1675. 
9. Serruys P, et al. N Engl J Med. 2010;363:136-146. 
10. Généreux P, et al. Circ Cardiovasc Interv. 2015;8(5):1-16; Natsuaki et al., Cardiovasc Interv and Ther. 2016. 31:196–209; Watanabe H, et al. JAMA. 2019;321(24):2414-2427; Hahn J, et al. ACC 2019 – SMART CHOICE; Valgimigli M, et al. Circulation. 2012;125:2015-2026; Gilard M, et al. J Am Coll Cardiol 2015;65:777-786; Hong SJ, et al. J Am Coll Cardiol Intv. 2016;9:1438–1446. Gwon HC, et al. ACC 2011 - EXCELLENT. 
11. Généreux P, et al. Circ Cardiovasc Interv. 2015;8(5):1-16; Natsuaki et al., Cardiovasc Interv and Ther. 2016. 31:196–209 - STOPDAPT; Watanabe H, et al. JAMA. 2019;321(24):2414-2427 – STOPDAPT 2; Hahn J, et al. ACC 2019 – SMART CHOICE; Watanabe H, et al. TCT 2019 – STOPDAPT 2 – HBR SubAnalysis; Varenne O, et al. 2018. Lancet. 391:41-50 – SENIOR; Kirtane A, et al. TCT 2019 – EVOLVE Short DAPT. Windecker S, et al. TCT 2019 – OnyxOne; Postma W, et al. 2019. Cather Cardiovasc Inter. 1-5 – DAPT STEMI. 
12. Natsuaki et al., Cardiovasc Interv and Ther. 2016. 31:196–209. Watanabe H, et al. JAMA. 2019;321(24):2414-2427. Watanabe H, et al. Cardiovasc Interv and Ther 2020. doi.org/10.1007/s12928-020-00651-9. 
13. Baron S, et al. J Am Coll Cardiol. 2017;70:3113-3122. 
14. Kufner S, et al. Circulation. 2019:139(3):325-333. Shiomi H, et al. J Am Coll Cardiol Interv. 2019;12:637-647. 
15. Data on file at Abbott. 15,000,000 implants number is based on data of DES implants through Q1, 2020. 
16. Zanchin, C. et al. J Am Coll Cardiol Intv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. J Am Coll Cardiol Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. 
17. Kufner S, et al. Circulation. 2019;139(3):325-333.

Date of preparation: May 2021. SFM_ABO1755.

MAT-2105209 v2.0

 

Abbott Logo

Information contained herein for distribution in Australia and New Zealand only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2023 Abbott. All Rights Reserved.

Abbott Vascular Division of Abbott Medical Australia Pty Ltd: 299 Lane Cove Road, Macquarie Park NSW 2113. Phone: 1800 550 939

Abbott Vascular Division of Abbott Medical New Zealand Limited: Grd Flr, Bldging D, 4 Pacific Rise, Mount Wellington Auckland 1060. Phone: 0800 827 285

MAT-2105201 v4.0

Disclaimer

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

 

Do you wish to continue and enter this website?

MAT-2105201 v1.0